Here’s a gut-wrenching reality for Memphis Grizzlies fans: their star guard, Ja Morant, is still sidelined with lingering elbow discomfort, and now Kentavious Caldwell-Pope is headed for finger surgery. But here’s where it gets controversial—how much longer can the Grizzlies afford to wait for Morant’s return, especially after trading away Jaren Jackson Jr. at the deadline? Let’s break it down.
Memphis Grizzlies fans are in for a prolonged wait as Ja Morant, the team’s dynamic guard, will sit out at least two more weeks due to ongoing recovery from a sprained ulnar collateral ligament in his left elbow. The injury, which occurred on January 21, has kept Morant off the court for a significant portion of the season. According to a Wednesday announcement, the two-time All-Star is making progress in his rehabilitation but continues to experience discomfort. The team plans to re-evaluate his condition in two weeks, leaving fans and analysts alike wondering about the long-term impact on the Grizzlies’ playoff aspirations.
And this is the part most people miss—while Morant’s injury is a major setback, the Grizzlies’ decision to retain him at the trade deadline, despite swirling rumors, speaks volumes about their commitment to his future with the team. Instead, they traded Jaren Jackson Jr. to the Utah Jazz, a move that has sparked debates about the team’s direction. Morant, who has played just 20 games this season, averages 19.5 points, 7.4 assists, and 4.6 rebounds, making his absence all the more glaring.
Adding to the team’s woes, Kentavious Caldwell-Pope will undergo surgery on Thursday to correct a misalignment in his right pinky finger. The 33-year-old guard, who has been a steady presence this season with averages of 8.4 points, 2.7 assists, and 2.5 rebounds in 51 games, will have his recovery timeline announced post-surgery. This dual setback raises questions about the Grizzlies’ depth and their ability to stay competitive in a tight Western Conference race.
Here’s the bold question for fans: Is the Grizzlies’ future still tied to Ja Morant’s health, or should the team reconsider its strategy in light of recurring injuries and recent trades? Let us know your thoughts in the comments—this is a debate that’s sure to divide opinions.
